FDA should take steps to strengthen the regenerative medicine industry.
After Congress adopted the 21st Century Cures Act in 2016, giving the U.S. Food and Drug Administration (FDA) authority to streamline the approval process for qualifying regenerative medicine advanced therapies (RMATs), FDA announced a new regulatory framework for the regenerative medicine industry.
The policys framework included new and revised guidance documents, as well as a period of enforcement discretion that has allowed industry participants to engage with FDA to determine if they needed to apply for FDA marketing authorization. As the end of the enforcement discretion period approaches, regulators must provide additional assistance to the RMAT industry to ensure its further development.
FDAs Center for Biologics Evaluation and Research regulates stem cell and other regenerative medicine products, but last year was also tasked with overseeing vaccine and drug development for COVID-19. Under the original FDA policy, the period of enforcement discretion would have ended in November 2020, but likely due to the COVID-19 crisis, FDA announced that it would extend the period through May 2021.
During the enforcement discretion period, FDA has designated 52 products so far for its RMAT approval process. FDA approved one such product earlier this year, a positive sign that it is fulfilling its mission under the 21st Century Cures Act to approve cellular products for the treatment of complex, previously incurable conditions.
Nevertheless, compliance has been slower than expected, and in spite of its enforcement discretion, FDA has continued to act against bad actors, typically in the form of warning letters to manufacturers and promoters of products derived from donated birth tissue, as well as public safety notifications and consumer alerts. It was no surprise when FDAand the Federal Trade Commission (FTC) in some instancesbegan targeting unapproved stem cell products advertised as miracle cures for COVID-19.
Consequently, a binary picture of the RMAT industry has developed, with legacy biotech firms seeking FDA approvals at one end of the spectrum, sellers of snake oil on the other, and not much in between.
But this picture is incomplete. In reality, there is much more to this industrysuch as licensed practitioners who have safely treated patients with their own tissue for yearsand these practitioners have found themselves caught in the crossfire, with the media routinely lumping them into the pool of bad actors.
But are the practicing physicians treating their patients at many major institutions breaking the law? Of course not.
In addition to defining what products are regulated, FDA regulations also exempt certain procedures, such as when a doctor uses autologous platelet-rich plasma or bone marrow concentrate to treat certain conditions.
When doctors perform these exempted medical procedures, the question of whether they do so responsibly is answered by the quintessentially state-law standards of reasonable medical care, which also define whether physicians have sufficient data and provide remedies in the event of malpractice.
Nor are these physicians experimenting on their patients. Medical procedures are developed differently than mass-produced drugs, and mostly without the large pre-market trials called for by the media. As an example, doctors have treated patients using coronary artery bypass grafts for 100 years, and the procedures have continually evolved based on physician research in clinical settings.
Another exempted procedure, a parathyroidectomy with subsequent implantation of a portion of the tissue to preserve parathyroid function, was first studied in the early 1970s on 29 patients in a clinical setting and reported in 1975. Based on that initial study, the procedure soon became a widely accepted technique and is now expressly exempt from FDA regulation.
Of course, these exempted procedures also occupy a different portion of the market than regulated cellular products. For instance, concentrated autologous bone marrow may be an optimal treatment modality for patients suffering from minor orthopedic conditions and is already available at a relatively low cost.
For patients with more severe or acute injuries, however, culture-expanded cell-based treatments are likely a better option, but only one has been approved since 1997. That product, which involves culture-expanded cartilage-derived cells, costs over $40,000. Due to its high price, the product is not reimbursable for patients with mere osteoarthritis. This phenomenon is common among approved drugs.
In sum, for all of its dimensions, the regenerative medicine industry is defined poorly, and better regulatory support is needed for it to mature. FDA should take the following regulatory steps with permanence and structure in mind.
First, FDA should continue honoring its mandate under the 21st Century Cures Act by designating and approving RMAT therapies with the urgency they deserve.
Second, FDA should recognize its role as a federal regulator, well suited to continue enforcing against bad actors, and particularly those manufacturing and distributing unapproved birth tissue products in interstate commerce.
Third, FDA must recognize its limitations. As a federal regulator, it is poorly suited to oversee and regulate every doctor in the country, as those police powers have historically been left to the individual states.
Fourth, in May, FDA should end its era of enforcement discretion. The industry has had sufficient time to study FDA regulations and establish compliance.
Finally, to balance its resources and priorities, it is critical that FDA invites the individual states, medical boards, and accrediting organizations to pitch in on its regulation of the industry. Indeed, state laws typically define and govern the standards for medical procedures, but state laws defining and governing regenerative medicine procedures are at best underdeveloped. To bridge this gap, FDA should establish partnerships similar to those that help it shoulder its massive burden of regulating food, animal food, eggs, blood banks, medical devices, and mammography facilities.
The Mammography Quality Standards Act (MQSA) is a sound analog. In 1990, the U.S. General Accounting Office determined that most mammography facilities lacked adequate quality assurance programs and were providing images of unacceptable quality. In response, the MQSA authorized FDA to publish quality standards and create accrediting bodies to inspect facilities and enforce FDAs quality standards. The MQSA remains the law today, and FDAs MQSA Inspection Contract Program features 42 contracts with state, local, and territorial agencies, as well as the American College of Radiology.
FDA can create a similar partnership program for the exempt and lower risk portions of the regenerative medicine industry with the following key features:
By taking these actions, FDA will preserve its resources, provide individual states the direction they need to exercise their police powers, and allow the regenerative medicine industry to reach its true potential.
The rest is here:
- New Cell Therapy Shows Promise in Treating HIV - BioSpace - May 14th, 2021
- The Worldwide Stem Cell Therapy Industry is Projected to Reach $401 Million by 2026 at a CAGR of 16.5% from 2021 - PRNewswire - May 14th, 2021
- Global Stem Cell Reconstructive Market 2021 Top Players Osiris Therapeutics, NuVasive, Cytori Therapeutics, Takeda (TiGenix), Cynata, Celyad,... - May 14th, 2021
- ONLINE: The Future of Heart Care - Isthmus - May 14th, 2021
- Rinri Therapeutics Secures Innovate UK Funding Grant for 3.2m Project to Advance its Novel Cell-Based Therapy to Restore Hearing Loss - PRNewswire - May 14th, 2021
- Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency Programs... - May 14th, 2021
- Cytovia Therapeutics Expands Leadership Team - GlobeNewswire - May 14th, 2021
- Stem Cell and Regenerative Therapy Market COVID-19 impact analysis, segmentation, key players, opportunities and forecast 2020 - 2026 - WhaTech - May 14th, 2021
- Comprehensive Atlas of Reef-Building Corals Cells Created - The Scientist - May 14th, 2021
- Fascination with stem cell sensation leads to Fulbright scholarship - Monash University - May 12th, 2021
- The Competitive Zeal To Decide The Dimensions Of Growth Of The Induced Pluripotent Stem Cells Market The Courier - The Courier - May 12th, 2021
- Gene therapy offers potential cure to children born without an immune system - UCLA Newsroom - May 12th, 2021
- With $52 Million Series A, Appia Bio Anticipates a Bright Future in Cell Therapy - BioSpace - May 12th, 2021
- Advanced Therapy Medicinal Products Market Size Worth $21.2 Billion By 2028: Grand View Research, Inc. - PRNewswire - May 12th, 2021
- The Univer-cell Alchemist: Dr Subhadra Dravidas breakthrough research on novel stem cell treatment for Covid patients - The New Indian Express - May 10th, 2021
- Stem Cell Therapy Market 2021-2026: Industry Analysis, Geographical Segmentation, Drivers, Challenges, and Trend & Forecasts KSU | The Sentinel... - May 9th, 2021
- Hope, hype and exploitation the wild history of stem cell science - ABC News - May 2nd, 2021
- Scientists create first-of-its-kind 3D organoid model of the human pancreas - Newswise - May 2nd, 2021
- Researchers map the first complete atlas of single cells that make up the human teeth - News-Medical.net - April 30th, 2021
- Researchers develop first 3D organoid models of the pancreas from human stem cells - News-Medical.net - April 30th, 2021
- The first comprehensive single-cell atlas of human teeth - Newswise - April 30th, 2021
- Revotek Deploys Its Bioink Technology to Research Institutes - PRNewswire - April 30th, 2021
- Rocket Pharmaceuticals Announces Upcoming Clinical Data Presentations at the 24th Annual Meeting of the American Society of Gene and Cell Therapy -... - April 30th, 2021
- Controversial experiment with human cells growing in monkey embryos | Science and Health - SwordsToday.ie - April 30th, 2021
- Adipose Tissue-Derived Stem Cells (ADSCS) Market Value with Volume and Growth Prospects 2021 to 2027 The Courier - The Courier - April 30th, 2021
- Placental-derived stem cell therapy shows promise to heal intestinal disease in premature babies - News-Medical.Net - April 28th, 2021
- Tissue Regeneration Market: Stem Cell Therapy to be Highly Attractive Segment - BioSpace - April 28th, 2021
- Repairing stroke and Alzheimer's disease damage with stem cell therapy - Health Europa - April 28th, 2021
- Stem Cell Therapy Global Market Report 2021: COVID-19 Growth And Change To 2030 - Yahoo Finance - April 28th, 2021
- Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 2021 Annual Meeting - PRNewswire - April 28th, 2021
- Vitro Biopharma Inc. January 31st 2021, 1st Quarter ended Financial Results of Operations and Shareholder Letter - Benzinga - April 28th, 2021
- Longeveron Selected to Present at the 2021 World Stem Cell Summit - GlobeNewswire - April 28th, 2021
- Prostate organoid technology - the new POT of gold in prostate stem cell and cancer research - DocWire News - April 28th, 2021
- University of Illinois Urbana-Champaign and Mayo Clinic Researchers Develop New Technique to Study 'Microcancers' and Screen Cancer-Fighting Drugs -... - April 28th, 2021
- Research with fetal tissue from elective abortion called 'deeply offensive' - Catholic San Francisco - April 28th, 2021
- Integration of Cellular Therapy Jumpstarts Research Efforts in Acute Leukemias - OncLive - April 28th, 2021
- Stem Cell Therapy for Diabetes and Related Conditions Market 2021 Competitive Insights Sanofi, Novo Nordisk, Mesoblast, Caladrius Biosciences,... - April 26th, 2021
- This technology was designed to grow human cells. Now it's transforming the cultured meat industry. - Massive Science - April 26th, 2021
- Global Canine Stem Cell Therapy Market is Projected to Grow at a CAGR of 9.3% during (2018 2026) NeighborWebSJ - NeighborWebSJ - April 26th, 2021
- Top Key-Players To Be Restored To The First Position In The Recombinant Cell Culture Supplements Market The Courier - The Courier - April 26th, 2021
- Hematopoietic Stem Cell Transplantation (HSCT) Global Market Report (2020-2027) Segmented by Type, Application and region (NA, EU, and etc.) The... - April 26th, 2021
- Three-dimensional microscale hanging drop arrays with geometric control for drug screening and live tissue imaging - Science Advances - April 24th, 2021
- Stem Cell Banking Market: Rise in Incidence of Chronic Conditions to Drive the Market - BioSpace - April 24th, 2021
- How Brown neuroscientists are using CRISPR to accelerate brain research and more - Brown University - April 24th, 2021
- Biotechnology in BCfuture treatments and potential cures for cancer - UBC Faculty of Medicine - UBC Faculty of Medicine - April 24th, 2021
- Scientists have moved closer to making organisms that are part human and part animal - Scroll.in - April 24th, 2021
- Impact of COVID-19 on Stem Cell Therapy Market is Booming Worldwide with Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene,... - April 24th, 2021
- Single-Use Bioreactors Market by Type of Reactor, Scale of Operation, Cell Culture System, Type of Molecule, Application Area, Purpose, End-User, and... - April 24th, 2021
- Stem cell therapy promotes recovery from stroke and dementia in mice - UCLA Newsroom - April 22nd, 2021
- Accelerating Cures Through Research - New York Stem Cell ... - April 22nd, 2021
- Stem cell therapy can repair brain damage and improve memory function in mice - News-Medical.Net - April 22nd, 2021
- 'Re-imagining' mice and men - The Highland County Press - April 22nd, 2021
- Research with fetal tissue from elective abortion called 'deeply offensive' - The Catholic Sun - April 22nd, 2021
- Research with fetal tissue from abortion called 'deeply offensive' - CatholicPhilly.com - April 22nd, 2021
- Do our brains age faster than the rest of our bodies? - ScienceBlog.com - April 22nd, 2021
- Study discovers mechanism involved in the development of metaplasia in the esophagus - News-Medical.Net - April 22nd, 2021
- Research Reveals Distinct Types of Cells That May Be Involved in Breathing-Related Diseases in Infants - Technology Networks - April 22nd, 2021
- Breakthrough Paper Outlines Path to Heart Regeneration After Cardiac Injury - PR Web - April 22nd, 2021
- Stem Cells Market to Witness Robust Expansion Throughout the Forecast Period 2018-2026 KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - April 20th, 2021
- Animal Stem Cell Therapy Market Study Report and In-deep Analysis 2020 2026 The Courier - The Courier - April 20th, 2021
- Global Cord Blood Stem Cells Market to 2026 Industry Perspective, Comprehensive Analysis, and Forecast KSU | The Sentinel Newspaper - KSU | The... - April 20th, 2021
- Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell... - April 18th, 2021
- StemSynergy Therapeutics' Notch1-Selective Small Molecule Inhibitor Prevents Tumor Growth by Ablation of Cancer Stem Cells - Business Wire - April 16th, 2021
- US researchers create the first human-monkey chimaera, in the midst of a raging debate on such experimentation - The Financial Express - April 16th, 2021
- CAR T-Cell Therapy Enters the Arena in Multiple Myeloma With Ongoing Research Ahead - OncLive - April 16th, 2021
- Treating chronic myeloid leukemia (CML): By phase and more - Medical News Today - April 16th, 2021
- Cellino Biotech developing tech to help scale stem cell therapies - MedCity News - April 14th, 2021
- Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Methods of Commercializing iPSCs are Diverse and Continue to Expand -... - April 14th, 2021
- A Massive New Gene Editing Project Is Out to Crush Alzheimer's - Singularity Hub - April 14th, 2021
- eQcell Inc Announces the Appointment of Members of the Board of Directors - BioSpace - April 14th, 2021
- Researchers Receive Grant to Improve Cellular Therapies to Treat 'Incurable' Diseases - University of Arkansas Newswire - April 14th, 2021
- Lonza Celebrates 20th Anniversary of Nucleofector Cell Transfection Platform - Technology Networks - April 14th, 2021
- New consortium aims to accelerate development of stem cell-based therapies for Huntingtons disease - News-Medical.Net - April 10th, 2021
- Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021: Research, Patents, Funding Events, Industry Partnerships, Biomedical... - April 10th, 2021
- Stem Cell Transplantation May Be Offered Less Often as a Treatment Option for Some Patients with Mantle Cell Lymphoma - Curetoday.com - April 10th, 2021
- Real-time imaging shines light on the coordination of neural stem cell activation - News-Medical.net - April 10th, 2021
- Searching for Molecular Targets in Myeloid Malignancies and Beyond - OncLive - April 10th, 2021
- Fitore Nutrition Launches Spectrum + to Better the Lives of Children With Autism - Influencive - April 10th, 2021
- Cancer Stem Cells Market By Size Estimation, Growth Rate, Regional Analysis With with the CAGR of 11.0% Over the Forecast Period. KSU | The Sentinel... - April 10th, 2021
- global market for regenerative medicines is predicted to grow at a CAGR of 13.99% over the forecast period of 2020-2030 - GlobeNewswire - April 10th, 2021